Abstract:Background: Cell and gene therapy products (CGTPs) often receive accelerated approvals, lacking comprehensive long-term safety and efficacy data, which can raise significant safety concerns. This research aims to study the post-marketing surveillance (PMS) of CGTPs in the European Union (EU), the United States (US), Japan, South Korea, and China, to offer insights for the development of a secure and standardized post-marketing regulatory framework for CGTPs. Methods: Related regulations and the implementation effect of PMS for approved CGTPs were studied searching PubMed, CNKI, and the official websites of the European Medicines Agency, the US Food and Drug Administration, Japan's Pharmaceuticals and Medical Device Agency, South Korea's Ministry of Food and Drug Safety, and the National Medical Products Administration of China. Results: Compared to those in China, the guidelines of PMS for CGTPs in the EU, the US, Japan, and South Korea was more comprehensive. Notably, the EU had dedicated regulations and supporting guidelines of PMS. Of the 26 CGTPs approved in the EU, 88% were under additional monitoring, 38% received conditional marketing authorization, and 12% were authorized under exceptional circumstances, with 77% designated as orphan drugs. The US had released 34 guidelines specifically for CGTPs which, forming the foundation of post-marketing risk management. Among the 27 CGTPs approved in the US, 22% were required to perform risk evaluation and mitigation strategies, 37% added black box warnings in the package inserts, 63% mandated to post-marketing requirements, and 15% subject to post-marketing commitments. In Japan, stringent supervision measures encompassing all-case surveillance (79%) and re-examination (53%) were applied to the 19 approved CGTPs, with 21% approved through conditional and time-limited approval. The PMS for CGTPs in South Korea, mainly included PSUR, re-examination, and re-evaluation. China had introduced several relevant regulations, which consisted of general statements and lacked detailed guidance. Conclusions: This study demonstrates that the regulatory policies of PMS for CGTPs in the EU, the US, Japan, and South Korea were comprehensive. The implementation of PMS for CGTPs in the EU, the US, and Japan was well developed. This knowledge holds valuable insights for China's future learning and development in this field.

Bayesian network analysis of risk classification strategies in the regulation of cellular products

Identification of the Risks in CAR T-cell Therapy Clinical Trials in China: a Delphi Study.

Regulatory Oversight of Cell Therapy in China: Government's Efforts in Patient Access and Therapeutic Innovation.

Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity

Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study

Clinical Application and Risk Assessment of CAR-T Cell Technology in Cancer Immunotherapy

How do I: Evaluate the safety and legitimacy of unproven cellular therapies?

Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China

Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines

Cell and gene therapy approvals in Japan and the need for international harmonization

Proceedings: International Regulatory Considerations on Development Pathways for Cell Therapies

Scalable optimal Bayesian classification of single-cell trajectories under regulatory model uncertainty

Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon

Search, identification, and curation of cell and gene therapy product regulations using augmented intelligent systems

Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies

Bayesian approach enabled objective comparison of multiple human iPSC-derived Cardiomyocytes' Proarrhythmia sensitivities.

Cell-based therapy technology classifications and translational challenges

Immunogenicity Risk Assessment of Process-related Impurities in an Engineered T cell Receptor Cellular Product

Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective

Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database